Enhancing selegiline hydrochloride efficacy: Box Behnken-optimized liposomal delivery via intranasal route for Parkinson’s disease intervention

References

• Gupta BM, Bala A. Parkinson’s disease in India: an analysis of publications output during 2002–2011. Int J Nutr Pharmacol Neurol Dis. 2013;3(3):254–262. doi: 10.4103/2231-0738.114849.
   Google Scholar
• Jellinger KA. Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med. 2010;14(3):457–487. doi: 10.1111/j.1582-4934.2010.01010.x.
   PubMed Web of Science ®Google Scholar
• Khot KB, Gopan G, Bandiwadekar A, et al. Current advancements related to phytobioactive compounds based liposomal delivery for neurodegenerative diseases. Ageing Res Rev. 2023;83:101806. doi: 10.1016/j.arr.2022.101806.
   PubMed Web of Science ®Google Scholar
• Bandiwadekar A, Khot KB, Gopan G, et al. Microneedles: a versatile drug delivery carrier for phytobioactive compounds as a therapeutic modulator for targeting mitochondrial dysfunction in the management of neurodegenerative diseases. Curr Neuropharmacol. 2024;22(6):1110–1128. doi: 10.2174/1570159X20666221012142247.
   PubMed Web of Science ®Google Scholar
• Lotankar S, Prabhavalkar KS, Bhatt LK. Biomarkers for Parkinson’s disease: recent advancement. Neurosci Bull. 2017;33(5):585–597. doi: 10.1007/s12264-017-0183-5.
   PubMed Web of Science ®Google Scholar
• Jenner P, Hunot O, Beal K, et al. Oxidative stress in Parkinson’s disease. Ann Neurol. 2003;53 Suppl 3(S3):S26–S38. doi: 10.1002/ana.10483.
   PubMedGoogle Scholar
• Abbas MM, Xu Z, Tan LCS. Epidemiology of Parkinson’s disease—east versus west. Movement Disord Clin Pract. 2018;5(1):14–28. doi: 10.1002/mdc3.12568.
   PubMed Web of Science ®Google Scholar
• Ray Dorsey E, Elbaz A, Nichols E, et al. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17(11):939–953. doi: 10.1016/S1474-4422(18)30295-3.
   PubMed Web of Science ®Google Scholar
• Willis AW, Roberts E, Beck JC, et al. Incidence of Parkinson disease in North America. NPJ Parkinsons Dis. 2022;8(1):170.
   PubMedGoogle Scholar
• Cerri S, Mus L, Blandini F. Parkinson’s disease in women and men: what’s the difference? J Parkinsons Dis. 2019;9(3):501–515. doi: 10.3233/JPD-191683.
   PubMedGoogle Scholar
• Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–376. doi: 10.1136/jnnp.2007.131045.
   PubMed Web of Science ®Google Scholar
• Joy D, Jose J, Bibi S, et al. Development of microneedle patch loaded with Bacopa monnieri solid lipid nanoparticles for the effective management of Parkinson’s disease. Bioinorg Chem Appl. 2022;2022:9150205. doi: 10.1155/2022/9150205.
   PubMed Web of Science ®Google Scholar
• Josephs KA, Matsumoto JY, Ahlskog JE. Benign tremulous Parkinsonism. Arch Neurol. 2006;63(3):354–357. doi: 10.1001/archneur.63.3.354.
   PubMedGoogle Scholar
• Mahul-Mellier AL, Burtscher J, Maharjan N, et al. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci USA. 2020;117(9):4971–4982. doi: 10.1073/pnas.1913904117.
   PubMed Web of Science ®Google Scholar
• Stoker TB, Barker RA. Recent developments in the treatment of Parkinson’s disease. F1000Research. 2020;9:862. doi: 10.12688/f1000research.25634.1.
   Google Scholar
• Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of Parkinsonism. N Engl J Med. 1967;276(7):374–379. doi: 10.1056/NEJM196702162760703.
   PubMed Web of Science ®Google Scholar
• Samii A, Nutt JG, Ransom BR. Parkinson’s disease. Lancet. 2004;363(9423):1783–1793. doi: 10.1016/S0140-6736(04)16305-8.
   PubMed Web of Science ®Google Scholar
• Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med. 2014;174(12):1930–1933. doi: 10.1001/jamainternmed.2014.5262.
   PubMed Web of Science ®Google Scholar
• Alborghetti M, Nicoletti F. Different generations of Type-B monoamine oxidase inhibitors in Parkinson’s disease: from bench to bedside. Curr Neuropharmacol. 2019;17(9):861–873. doi: 10.2174/1570159X16666180830100754.
   PubMed Web of Science ®Google Scholar
• Graves SM, Xie Z, Stout KA, et al. Dopamine metabolism by a monoamine oxidase mitochondrial shuttle activates the electron transport chain. Nat Neurosci. 2020;23(1):15–20. doi: 10.1038/s41593-019-0556-3.
   PubMed Web of Science ®Google Scholar
• Goldenberg MM. Medical management of Parkinson’s disease. P and T. 2008;33(10):590.
   Google Scholar
• Robakis D, Fahn S. Defining the role of the monoamine oxidase-B inhibitors for Parkinson’s disease. CNS Drugs. 2015;29(6):433–441. doi: 10.1007/s40263-015-0249-8.
   PubMed Web of Science ®Google Scholar
• Jiang L, Ding L, Liu G. Nanoparticle formulations for therapeutic delivery, pathogen imaging and theranostic applications in bacterial infections. Theranostics. 2023;13(5):1545–1570. doi: 10.7150/thno.82790.
   PubMed Web of Science ®Google Scholar
• Jagaran K, Singh M. Lipid nanoparticles: promising treatment approach for Parkinson’s disease. Int J Mol Sci. 2022;23(16):9361. doi: 10.3390/ijms23169361.
   PubMed Web of Science ®Google Scholar
• Liu P, Chen G, Zhang J. A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules. 2022;27(4):1372doi: 10.3390/molecules27041372.
   Web of Science ®Google Scholar
• Tosi G, Ruozi B, Vandelli MA. Brain targeting with polymeric nanoparticles: which administration route should we take? Nanomedicine. 2013;8(9):1361–1363. doi: 10.2217/nnm.13.135.
   PubMed Web of Science ®Google Scholar
• Emad NA, Ahmed B, Alhalmi A, et al. Recent progress in nanocarriers for direct nose to brain drug delivery. J Drug Deliv Sci Technol. 2021;64:102642. doi: 10.1016/j.jddst.2021.102642.
   Web of Science ®Google Scholar
• Feng Y, He H, Li F, et al. An update on the role of nanovehicles in nose-to-brain drug delivery. Drug Discov Today. 2018;23(5):1079–1088. doi: 10.1016/j.drudis.2018.01.005.
   PubMed Web of Science ®Google Scholar
• Illum L. Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems? J Pharm Sci. 2007;96(3):473–483. doi: 10.1002/jps.20718.
   PubMed Web of Science ®Google Scholar
• Lee D, Minko T. Nanotherapeutics for nose-to-brain drug delivery: an approach to bypass the blood brain barrier. Pharmaceutics. 2021;13(12):2049. doi: 10.3390/pharmaceutics13122049.
   PubMed Web of Science ®Google Scholar
• Costantino HR, Illum L, Brandt G, et al. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm. 2007;337(1–2):1–24.
   PubMed Web of Science ®Google Scholar
• Narayan R, Singh M, Ranjan OP, et al. Development of risperidone liposomes for brain targeting through intranasal route. Life Sci. 2016;163:38–45. doi: 10.1016/j.lfs.2016.08.033.
   PubMed Web of Science ®Google Scholar
• Yuwanda A, Surini S, Harahap Y, et al. Study of valproic acid liposomes for delivery into the brain through an intranasal route. SSRN J. 2021;8(3):e09030. doi: 10.2139/ssrn.3916202.
   Google Scholar
• Krishnaiah YSR, Jayaram B, Rama B, et al. Reverse-phase HPLC method for the estimation of selegiline hydrochloride in pharmaceutical dosage forms. Asian J Chem. 2003;15(3–4):1291–1296.
   Google Scholar
• Khute S, Jangde RK. Optimization of nasal liposome formulation of venlafaxine hydrochloride using a Box-Behnken experimental design. Curr Ther Res Clin Exp. 2023;99:100714. doi: 10.1016/j.curtheres.2023.100714.
   PubMed Web of Science ®Google Scholar
• Sailor G, Seth AK, Parmar G, et al. Formulation and in vitro evaluation of berberine containing liposome optimized by 32 full factorial designs. J App Pharm Sci. 2015;5(7):023–028. doi: 10.7324/JAPS.2015.50704.
   Google Scholar
• Okafor NI, Nkanga CI, Walker RB, et al. Encapsulation and physicochemical evaluation of efavirenz in liposomes. J Pharm Investig. 2020;50(2):201–208. doi: 10.1007/s40005-019-00458-8.
   Web of Science ®Google Scholar
• Chandran IS, Prasanna PM. Drug-excipient interaction studies of loperamide loaded in polsorbate 80 liposomes. Orient J Chem. 2015;31(4):2201–2206. doi: 10.13005/ojc/310443.
   Google Scholar
• Yang B. Preclinical study of doxorubicine-loaded liposomal drug delivery for the treatment of head and neck cancer: optimization by Box-Behnken statistical design. Acta Biochim Pol. 2020;67(2):149–155. doi: 10.18388/abp.2020_5142.
   PubMed Web of Science ®Google Scholar
• Ramalingam M, Huh YJ, Lee YI. The impairments of α-synuclein and mechanistic target of rapamycin in rotenone-induced SH-SY5Y cells and mice model of Parkinson’s disease. Front Neurosci. 2019;13:1028. doi: 10.3389/fnins.2019.01028.
   PubMed Web of Science ®Google Scholar
• Hoseinah SS, Akbarzadeh A, Attar H. Effect of cytotoxicity of pegylated liposomal recombinant human erythropoietin-alfa on neuroblastoma cell line SH-SY5Y. Trop J Pharm Res. 2015;14(6):977–981. doi: 10.4314/tjpr.v14i6.6.
   Web of Science ®Google Scholar
• Al Asmari AK, Ullah Z, Tariq M, et al. Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Des Devel Ther. 2016;10:205–215. doi: 10.2147/DDDT.S93937.
   PubMedGoogle Scholar
• Wang Y, Yu X, Zhang P, et al. Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson’s disease. J Pharmacol Sci. 2018;138(1):31–37. doi: 10.1016/j.jphs.2018.08.008.
   PubMed Web of Science ®Google Scholar
• Miyazaki I, Asanuma M. The rotenone models reproducing central and peripheral features of Parkinson’s disease. Neuroscience. 2020;1(1):1–14. doi: 10.3390/neurosci1010001.
   Google Scholar
• Sridhar V, Gaud R, Bajaj A, et al. Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson’s disease. Nanomedicine. 2018;14(8):2609–2618. doi: 10.1016/j.nano.2018.08.004.
   PubMed Web of Science ®Google Scholar
• Xiang Y, Wu Q, Liang L, et al. Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against the Parkinson’s disease in the MPTP-induced mice model. J Drug Target. 2012;20(1):67–75. doi: 10.3109/1061186X.2011.595490.
   PubMed Web of Science ®Google Scholar
• Bi Y, Qu PC, Wang QS, et al. Neuroprotective effects of alkaloids from piper longum in a MPTP-induced mouse model of Parkinson’s disease. Pharm Biol. 2015;53(10):1516–1524. doi: 10.3109/13880209.2014.991835.
   PubMed Web of Science ®Google Scholar
• Durak I, Yurtarslanl Z, Canbolat O, et al. A methodological approach to superoxide dismutase (SOD) activity assay based on inhibition of nitroblue tetrazaolium (NBT) reduction. Clin Chim Acta. 1993;214(1):103–104. doi: 10.1016/0009-8981(93)90307-p.
   PubMed Web of Science ®Google Scholar
• Merghem M, Dahamna S, Khennouf S. In vivo antioxidant activity of Ruta montana L. extracts. J Mater Environ Sci. 2019;10(5):470–477.
   Google Scholar
• Fikry H, Saleh LA, Abdel Gawad S. Neuroprotective effects of curcumin on the cerebellum in a rotenone-induced Parkinson’s disease model. CNS Neurosci Ther. 2022;28(5):732–748. doi: 10.1111/cns.13805.
   PubMed Web of Science ®Google Scholar
• Raj R, Wairkar S, Sridhar V, et al. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: development, characterization and in vivo anti-Parkinson activity. Int J Biol Macromol. 2018;109:27–35. doi: 10.1016/j.ijbiomac.2017.12.056.
   PubMed Web of Science ®Google Scholar
• Arif M, Rauf K, Sewell RD, et al. 6-Methoxyflavone and donepezil behavioral plus neurochemical correlates in reversing chronic ethanol and withdrawal induced cognitive impairment. Drug Des Devel Ther. 2022;16:1573–1593. doi: 10.2147/DDDT.S360677.
   PubMed Web of Science ®Google Scholar
• Motawi TK, Sadik NAH, Hamed MA, et al. Potential therapeutic effects of antagonizing adenosine A2A receptor, curcumin and niacin in rotenone-induced Parkinson’s disease mice model. Mol Cell Biochem. 2020;465(1–2):89–102. doi: 10.1007/s11010-019-03670-0.
   PubMed Web of Science ®Google Scholar
• Rane S, Prabhakar B. Optimization of paclitaxel containing pH-sensitive liposomes by 3 factor, 3 level Box-Behnken design. Indian J Pharm Sci. 2013;75(4):420–426. doi: 10.4103/0250-474X.119820.
   PubMed Web of Science ®Google Scholar
• Mishra N, Sharma S, Deshmukh R, et al. Development and characterization of nasal delivery of selegiline hydrochloride loaded nanolipid carriers for the management of Parkinson’s disease. Cent Nerv Syst Agents Med Chem. 2019;19(1):46–56. doi: 10.2174/1871524919666181126124846.
   PubMedGoogle Scholar
• Raman S, Khan AA, Mahmood S. Nose to brain delivery of selegiline loaded PLGA/lipid nanoparticles: synthesis, characterisation and brain pharmacokinetics evaluation. J Drug Deliv Sci Technol. 2022;77:103923. doi: 10.1016/j.jddst.2022.103923.
   Web of Science ®Google Scholar